Skip to main content

Major Depressive Disorder

November 26, 2019
The US Food and Drug Administration (FDA) recently granted Usona Institute, Madison, Wisconsin, the Breakthrough Therapy designation for psilocybin in the treatment of patients with major depressive disorder (MDD). The designation formalizes the FDA’s commitment to an efficient development program…
November 18, 2019
At both lower and higher doses, a yoga and breathing intervention improved symptoms of depression and anxiety in a group of people with major depressive disorder (MDD), according to a study published recently in the Journal of Psychiatric Practice.
November 04, 2019
People with mood or anxiety disorders demonstrate shared abnormalities in brain regions involved in emotional and cognitive control, according to a meta-analysis of brain scans published online in JAMA Psychiatry.
October 17, 2019
Deep brain stimulation of the subcallosal cingulate SCC DBS) appears to offer sustained antidepressant efficacy and long-term safety for patients with treatment-resistant depression for up to 8 years, according to a study published online in The American Journal of Psychiatry.
October 15, 2019
Antidepressant use appears to be safe, according to a systematic umbrella review of 45 meta-analyses spanning more than 1000 observational studies. Researchers published findings from their review online in JAMA Psychiatry.
October 05, 2019
SAN DIEGO—Mental health clinicians aren't talking to their patients enough about sexual dysfunction issues that could be resulting from use of antidepressants or the underlying depressive illness, University of Virginia Professor of Psychiatry Anita Clayton, MD, said at Psych Congress 2019.
October 04, 2019
SAN DIEGO—When added to ongoing treatment, pimavanserin significantly improved sexual function in patients with major depressive disorder, according to study results shared during poster sessions at Psych Congress 2019.
October 04, 2019
SAN DIEGO—Added to standard-of-care treatment, esketamine nasal spray rapidly reduced depressive symptoms in patients at imminent risk of suicide, according to two phase 3 trials presented at Psych Congress 2019.
October 04, 2019
SAN DIEGO—Major depressive disorder relapse is linked with higher health care utilization and costs, researchers reported during a poster session at Psych Congress 2019.
September 25, 2019
Sertraline eased anxiety symptoms and improved self-reported mental health within 6 weeks in primary care patients with symptoms of depression, according to a study published online in The Lancet Psychiatry.
Back to Top